Email Alert | RSS

Journal of Peking University(Health Sciences) ›› 2019, Vol. 51 ›› Issue (6): 1008-1013. doi: 10.19723/j.issn.1671-167X.2019.06.005

Previous Articles     Next Articles

Clinical characteristics of psoriatic arthritis with positive rheumatoid factor or anti-cyclic citrullinated peptide antibody

Li-yi DAI1,Dan-dan GONG2,Jin-xia ZHAO1,△()   

  1. 1. Department of Rheumatology, Peking University Third Hospital, Beijing 100191, China
    2. Department of Rheumatology, Handan First Hospital, Handan 056000, Hebei, China
  • Received:2019-08-26 Online:2019-12-18 Published:2019-12-19
  • Contact: Jin-xia ZHAO E-mail:zhao-jinxia@163.com

RICH HTML

   

PDF (PC)

Abstract:

Objective: To analyze the clinical and laboratory features of psoriatic arthritis (PsA) patients with positive rheumatoid factor(RF)or anti-cyclic citrullinated peptide(CCP)antibody.Methods: In the study, 77 PsA patients who were hospitalized in the Department of Rheumatology and Immunology of Peking University Third Hospital from January 2007 to June 2019 were enrolled. All the patients met Classification Criteria for Psoriatic Arthritis or Moll or Wright Criteria. Rheumatoid factor (RF) and anti-cyclic-citrullinated peptide (CCP) antibody were tested in these patients. According to whether anti-CCP antibody or RF was detected in serum, all the patients were divided into anti-CCP antibody or RF positive group (15 cases), anti-CCP antibody or RF negative group (62 cases). According to the detection of anti-CCP antibody in serum, all the patients were divided into anti-CCP antibody positive group (7 cases) and anti-CCP antibody negative group (70 cases). Clinical and laboratory data were collected. The differences of clinical and laboratory indicators between the RF or anti-CCP antibody positive and negative PsA patients were compared. Clinical and laboratory indicators between the anti-CCP antibody positive and negative patients were also compared.Results: Among the 77 patients, 15 were RF or anti-CCP antibody positive, of whom 8 were only RF positive and 2 were only anti-CCP antibody positive, and both of RF and anti-CCP antibody were positive in 5 cases. The RF or anti-CCP antibody positive PsA patients were older than those in the negative group [(58.2±14.8) years vs.(46.69±12.27)years, P=0.002]. And metacarpophalangeal joints, elbow joints and shoulder joints were more likely to be involved in RF or anti-CCP antibody positive PsA patients. PsA patients in the anti-CCP antibody positive group were older than those in the negative group [(62.43±14.34) years vs.(47.59±12.75)years old, P=0.005]. The positive rate of RF and serum level of fibrinogen in the anti-CCP antibody positive group were higher than those in the negative group. The PsA patients in the anti-CCP antibody positive group were all polyarthritis, while 68.6% patients in the negative group were polyarthritis, but there was no statistical difference between the two groups. There was no statistical difference in sausage fingers/toes, changes in nails and enthesitis, and bone erosion on radiographs between the RF or anti-CCP antibody positive and negative PsA patients. There was also no statistical difference in sausage fingers/toes,bone erosion on radiographs,and changes in nails and enthesitis between the anti-CCP antibody positive and negative patients.Conclusion: RF and anti-CCP antibodies can be detected in the serum of some PsA patients. RF or anti-CCP antibody positive PsA patients were older than those in negative PsA patients. Metacarpophalangeal joints, elbow joints and shoulder joints were more likely to be involved in RF or anti-CCP antibody positive PsA patients. Anti-CCP antibody positive PsA patients were older and had higher levels of RF positive rate and fibrinogen level.

Key words: Psoriatic arthritis, Rheumatoid factor, Anti-cyclic citrullinated peptide antibody

CLC Number: 

  • R593.2

Table 1

Comparison of general conditions of RF or anti-CCP antibody positive and negative PsA patients"

Items Positive group(n=15) Negative group(n=62) P
Male,n(%) 9(60.0) 35(56.45) 0.803*
Age /years, x?±s 58.2±14.8 46.69±12.27 0.002
The course of psoriasis/years, x?±s 15.04±12.57 13.79±12.41 0.727
The course of arthritis/years, M(Min, Max) 2(0.08,18.00) 1(0.02,20.00) 0.517

Table 2

Comparison of clinical characteristics of RF or anti-CCP antibody positive and negative PsA patients"

Items Positive group(n=15) Negative group(n=62) P
Shoulder joint involvement, n(%) 9(60.0) 16(25.8) 0.026#
Elbow joint involvement, n(%) 7(46.7) 11(17.7) 0.042#
Wrist joint involvement, n(%) 10(66.7) 26(41.9) 0.085*
MCP joint involvement, n(%) 11(73.3) 24(38.7) 0.016*
PIP joint involvement, n(%) 12(80.0) 33(53.2) 0.059*
DIP joint involvement, n(%) 6(40.0) 22(35.5) 0.744*
Hip joint involvement, n(%) 2(13.3) 7(11.3) 1.000#
Knee joint involvement, n(%) 11(73.3) 36(58.1) 0.277*
Ankle joint involvement, n(%) 6(40.0) 20(32.3) 0.569*
MTP joint involvement, n(%) 8(53.3) 23(37.1) 0.250*
PIP joint involvement of foot, n(%) 1(6.7) 15(24.2) 0.252#
DIP joint involvement of foot, n(%) 0(0.0) 9(14.5) 0.262#
Spinal involvement, n(%) 2(13.3) 7(11.3) 1.000#
Sacroiliac joint involvement, n(%) 2(13.3) 12(19.4) 0.865#
More than 3 articular regions involvement (14 articular regions), n(%) 13(86.7) 42(67.7) 0.255#
Wrist, MCP or PIP (hand) joint involvement, n(%) 14(93.3) 47(75.8) 0.252#
Symmetrical arthritis, n(%) 12(80.0) 34(54.8) 0.075*
Oligoarthritis (4 or less joints involved) , n(%) 2(13.3) 17(27.4) 0.423#
Sausage fingers/toes, n(%) 5(33.3) 18(30.5)(n=59) 1.000#
Changes in nails, n(%) 6(50.0)(n=12) 12(27.9)(n=43) 0.274#
Enthesitis, n(%) 2(16.7)(n=12) 15(34.9)(n=43) 0.393#
Psoriasis rash, n(%) 12(100.0)(n=12) 39(90.7)(n=43) 0.566▲

Table 3

Comparison of laboratory and imaging examinations in RF or anti-CCP antibody positive and negative PsA patients"

Items Seropositive group(n=15) Seronegative group(n=62) P
ESR/(mm/h), x?±s 55.15±30.89(n=13) 39.09±30.51(n=55) 0.067
CRP/(mg/L), x?±s 46.95(2.10, 173.00)(n=14) 24.70(1.00, 551.00)(n=59) 0.245
IgG/(g/L), x?±s 15.97±4.44(n=12) 13.47±3.02(n=45) 0.054
IgA/(g/L), x?±s 3.25±1.52(n=12) 3.23±1.28(n=46) 0.963
IgM/(g/L), x?±s 1.35±1.05(n=11) 1.15±0.53(n=45) 0.789
Fibrinogen/(g/L), x?±s 4.97±1.51(n=12) 4.38±1.38(n=44) 0.231
D-dimer/(mg/L), M(Min, Max) 0.78(0.11, 2.86)(n=12) 0.31(0, 2.76)(n=42) 0.121
Bone erosion on radiograph,n(%) 4(33.3)(n=12) 19(35.8)(n=53) 1.000#

Table 4

Comparison of the general conditions of anti-CCP antibody positive and negative PsA patients"

Items Anti-CCP antibody positive group
(n=7)		 Anti-CCP antibody negative group
(n=70)		 P
Male,n(%) 5(71.4) 39(55.7) 0.689#
Age /years, x?±s 62.43±14.34 47.59±12.75 0.005
The course of psoriasis/years, x?±s 13.14±6.20 14.13±12.85 0.873
The course of arthritis/years, M(Min, Max) 2(0.83, 18) 1(0.02, 20) 0.871
Duration between skin onset and arthritis onset/years, M(Min, Max) 7.9(-1, 20)(n=7) 9.3(-2, 45)(n=64) 0.825

Table 5

Comparison of clinical characteristics of anti-CCP antibody positive and negative PsA patients"

Items Anti-CCP antibody positive
group(n=7)		 Anti-CCP antibody negative
group(n=70)		 P
Shoulder joint involvement, n(%) 5(71.4) 20(28.6) 0.059#
Elbow joint involvement, n(%) 4(57.1) 14(20.0) 0.081#
Wrist joint involvement, n(%) 6(85.7) 30(42.9) 0.077#
MCP joint involvement, n(%) 6(85.7) 29(41.4) 0.065#
PIP joint involvement, n(%) 7(100.0) 38(54.3) 0.053#
DIP joint involvement, n(%) 3(42.9) 25(35.7) 1.000#
Hip joint involvement, n(%) 1(14.3) 8(11.4) 1.000▲
Knee joint involvement, n(%) 5(71.4) 42(60.0) 0.853#
Ankle joint involvement, n(%) 2(28.6) 24(34.3) 1.000#
MTP joint involvement, n(%) 3(42.9) 28(40.0) 1.000#
PIP joint involvement of foot, n(%) 1(14.3) 15(21.4) 1.000#
DIP joint involvement of foot, n(%) 0(0) 9(12.9) 0.590▲
Spinal involvement, n(%) 1(14.3) 8(11.4) 1.000▲
Sacroiliac joint involvement, n(%) 0(0) 14(20.0) 0.427#
More than 3 articular regions involvement(14 articular regions), n(%) 7(100.0) 48(68.6) 0.188#
Wrist, MCP or PIP(hand) joint involvement, n(%) 7(100.0) 54(77.1) 0.351#
Symmetrical arthritis , n(%) 6(85.7) 40(57.1) 0.287#
Oligoarthritis (4 or less joints involved), n(%) 0(0) 19(27.1) 0.259#
Sausage fingers/toes, n(%) 2(28.6)(n=7) 21(31.3)(n=67) 1.000#
Changes in nails, n(%) 2(50.0) (n=4) 16(31.4)(n=51) 0.833#
Enthesitis, n(%) 0(0) (n=4) 17(33.3)(n=51) 0.408#
Psoriasis rash, n(%) 4(100.0)(n=4) 47(92.2)(n=51) 1.000▲

Table 6

Comparison of laboratory and imaging examinations of anti-CCP antibody positive and negative PsA patients"

Items Anti-CCP antibody positive group(n=7) Anti-CCP antibody negative group(n=70) P
RF positive, n(%) 5(71.4) 8(11.4) <0.001#
ESR/(mm/h), x?±s 58.33±40.02(n=6) 40.60±29.95(n=62) 0.283
CRP/(mg/L), M(Min, Max) 69.2(2.1, 173.0)(n=7) 23.9(1.0, 551.0)(n=66) 0.459
IgG/(g/L), x?±s 13.90±4.10(n=5) 14.01±3.46(n=52) 0.902
IgA/(g/L), x?±s 3.57±2.02(n=5) 3.20±1.26(n=53) 0.687
IgM/(g/L), x?±s 1.50±1.58(n=5) 1.16±0.52(n=51) 0.635
Fibrinogen/(g/L), x?±s 5.87±1.30(n=4) 4.40±1.38(n=52) 0.048
D-dimer(mg/L), M(Min, Max) 0.92(0.59, 2.86)(n=4) 0.31(0, 2.76)(n=50) 0.071
Bone erosion on radiograph, n(%) 3(42.9)(n=7) 20(34.5)(n=58) 0.985#
[1] Korendowych E, Owen P, Ravindran J , et al. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis[J]. Rheumatology(Oxford), 2005,44(8):1056-1060.
[2] vander Cruyssen B, Hoffman IEA, Zmierczak H , et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis[J]. Ann Rheum Dis, 2005,64(8):1145-1149.
[3] Behrens F, Koehm M, Thaci D . Anti-citrullinated protein antibo-dies are linked to erosive disease in an observational study of patients with psoriatic arthritis[J]. Rheumatology, 2016,55(10):1791-1795.
[4] Hagiwara S, Tsuboi H, Terasaki T , et al. Association of anti-cyclic citrullinated peptide antibody with clinical features in patients with psoriatic arthritis[J]. Mod Rheumatol, 2019,29:1-8.
[5] Inanc N, Dalkilic E, Kamali S , et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis[J]. Clin Rheumatol, 2007,26(1):17-23.
[6] Taylor W, Gladman D, Helliwell P . Classification criteria for psoriatic arthritis: Development of new criteria from a large international study[J]. Arthritis Rheum, 2006,54(8):2665-2673.
[7] Moll JM, Wright V . Psoriatic arthritis[J]. Semin Arthritis Rheum, 1973,3(1):55-78.
[8] Aletaha D, Neogi T, Silman AJ , et al. 2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Arthritis Rheum, 2010,62(9):2569-2581.
[9] Zhao J, Su Y, Li R , et al. Classification criteria of early rheumatoid arthritis and validation of its performance in a multi-centre cohort[J]. Clin Exp Rheumatol, 2014,32(5):667-673.
[10] Inui K, Okano T, Yoshimura H , et al. Clinical features of rheumatoid factor- or anti-cyclic citrullinated peptides-positive patients with psoriatic arthritis[J]. Ann Rheum Dis, 2017,76(Suppl 2):1324.
[11] Eker YÖ, Pamuk ON, Pamuk GE , et al. The frequency of anti-CCP antibodies in patients with rheumatoid arthritis and psoriatic arthritis and their relationship with clinical features and parameters of angiogenesis: A comparative study[J]. Eur J Rheumatol, 2014,1(2):67-71.
[12] Popescu C, Zofota S, Bojinca V , et al. Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis: Cross-sectional study and literature review[J]. J Med Life, 2013,6(4):376-382.
[13] Ritchlin CT, Colbert RA, Gladman DD . Psoriatic arthritis[J]. New Engl J Med, 2017,376(10):957-970.
[14] OzdemirIsik O, Cosan F, Yazici A , et al. The clinical assessment of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis[J]. Ann Rheum Dis, 2016,75(Suppl 2):1151
[15] Merola JF, Espinoza LR, Fleischmann R . Distinguishing rheumatoid arthritis from psoriatic arthritis[J]. RMD Open, 2018,4(2):1-13.
[1] SONG Zhi-bo,GENG Yan,DENG Xue-rong,ZHANG Xiao-hui,ZHANG Zhuo-li. Benefit of ultrasound in the phenotype recognition of psoriatic arthritis [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1061-1066.
[2] Yan GENG,Zhi-bo SONG,Xiao-hui ZHANG,Xue-rong DENG,Yu WANG,Zhuo-li ZHANG. Depression and anxiety in patients with psoriatic arthritis: Prevalence and associated factors [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1048-1055.
[3] Jing-feng ZHANG,Xiu-ling YE,Meng DUAN,Xiao-li ZHOU,Zhong-qiang YAO,Jin-xia ZHAO. Clinical and laboratory characteristics of rheumatoid arthritis with positive antinuclear antibody [J]. Journal of Peking University (Health Sciences), 2020, 52(6): 1023-1028.
[4] Yu-hui LI,Bo SU,Fu-an LIN,Ya-nan FEI,Xiao-xia YU,Wen-qiang FAN,Hai-ying CHEN,Xue-wu ZHANG,Yuan JIA. Cross-sectional study on clinic behavior and therapeutic status of patients with psoriatic arthritis in multi-center [J]. Journal of Peking University(Health Sciences), 2019, 51(6): 1014-1018.
[5] SHI Lian-jie， LI Jian-hong， HU Fan-lei， LI Min， ZHANG Jie， LI Jiang-tao， LI Zhan-guo. Clinical significance of serum C-C chemokine ligand 19 levels in patients with rheumatoid arthritis [J]. Journal of Peking University(Health Sciences), 2016, 48(4): 667-671.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd